Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 3Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Thrombocytopenia 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

eltrombopag 3Platelet Transfusion 2Busulfan 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2siltuximab 1oprelvekin 1fludarabine phosphate 1fludarabine 1Vitamin E 1Tranexamic Acid 1Topotecan 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Microarray Analysis 1Isotretinoin 1Interleukin-11 1Hematopoietic Stem Cell Transplantation 1Gene Expression Profiling 1Flow Cytometry 1Filgrastim 1Etoposide 1Decitabine 1DNA Methylation 1Cytogenetic Analysis 1Cytarabine 1Cyclophosphamide 1Biopsy 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocytopenia × oprelvekin × Myeloid × Clear all
NCT00493181 2012-02-20

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

M.D. Anderson Cancer Center

Phase 2 Completed
8 enrolled 3 charts
Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡